Clinical trial
The Switch Study: The Role of Lamivudine/Emtricitabine (3TC/FTC) in…
NCT00152061 · Stanford University, Other · Completed
Key facts
| NCT number | NCT00152061 |
|---|---|
| Title | The Switch Study: The Role of Lamivudine/Emtricitabine (3TC/FTC) in Antiretroviral Regimens |
| Official title | The Role of 3TC/FTC in Partially Suppressive Antiretroviral Regimens: The Switch Study |
| Lead sponsor | Stanford University, Other |
| Collaborators | Santa Clara Valley Health & Hospital System University of California, Davis |
| Status | Completed |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | 3TC and FTC |
| Enrollment | 40 |
| Start date | Jan 1, 2005 |
| Completion | Aug 1, 2005 |
| First posted | Sep 9, 2005 |
| Last update posted | Jun 19, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: